Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicentre, randomized controlled trial (PREPOSTEROUS trial)

Oslo University Hospital HF2 sites in 1 country500 target enrollmentDecember 19, 2024

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Not specified
Sponsor: Oslo University Hospital HF
Enrollment: 500
Locations: 2
Primary Endpoint: Venous thromboembolisms, number of patients, within 30 days from liver resection.
Status: Recruiting
Last Updated: last year

Perioperatively initiated thromboprophylaxis reduces venous thromoboembolism without increasing the risk of bleeding complications.

Registry

euclinicaltrials.eu

Start Date

December 19, 2024

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sponsor

Oslo University Hospital HF

Responsible Party

Principal Investigator

Sheraz Yaqub

Scientific

Oslo University Hospital HF

•Patient on anti-coagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery. Emergency operation (e.g., for trauma or infection). Age < 18 years Allergy or other contraindication to planned low-molecular weight heparin. Inability to give written informed consent. Liver resection not performed (removed from analyses after randomization).

Venous thromboembolisms, number of patients, within 30 days from liver resection.

1) Posthepatectomy haemorrhage, any grade in ISGLS classification, number of patients, within 30 days from liver resection 2) Comprehensive Complication Index – score, within 30 days from liver resection 3) Length of postoperative hospital stay, days 4) Total amount of transfused red blood cells, units, during and within 30 days from liver resection